{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T21:22:56Z","timestamp":1794691376940,"version":"4.9.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.euroneuro.2023.03.015","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T13:53:30Z","timestamp":1681739610000},"page":"40-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Antipsychotic-induced akathisia in adults with acute schizophrenia: A systematic review and dose-response meta-analysis"],"prefix":"10.1016","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1211-7439","authenticated-orcid":false,"given":"Hui","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8264-2039","authenticated-orcid":false,"given":"Spyridon","family":"Siafis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1773-6933","authenticated-orcid":false,"given":"Angelika","family":"Burschinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3448-9532","authenticated-orcid":false,"given":"Johannes","family":"Schneider-Thoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Priller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2023.03.015_bib0001","doi-asserted-by":"crossref","unstructured":"128-301 S (1997) Study report of study 128-301, Pfizer, data on file.","DOI":"10.1111\/j.1365-246X.1997.tb01556.x"},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0002","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evidence Based Mental Health"},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0003","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0004","first-page":"1","article-title":"Akathisia and atypical antipsychotics: relation to suicidality, agitation and depression in a clinical trial","author":"Bjarke","year":"2022","journal-title":"Acta Neuropsychiatr."},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0005","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1192\/bjp.143.2.139","article-title":"Clinical characteristics of akathisia: a systematic investigation of acute psychiatric inpatient admissions","volume":"143","author":"Braude","year":"1983","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0006","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1002\/1097-0258(20001130)19:22<3127::AID-SIM784>3.0.CO;2-M","article-title":"A simple method for converting an odds ratio to effect size for use in meta-analysis","volume":"19","author":"Chinn","year":"2000","journal-title":"Stat. Med."},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0007","first-page":"233","article-title":"The extrapyramidal symptoms rating scale","volume":"7","author":"Chouinard","year":"1980","journal-title":"Can. J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.euroneuro.2023.03.015_bib55","doi-asserted-by":"crossref","first-page":"20m13602","DOI":"10.4088\/JCP.20m13602","article-title":"Efficacy and Safety of HP-3070, an Asenapine Transdermal System, in Patients With Schizophrenia: A Phase 3, Randomized, Placebo-Controlled Study","volume":"82","author":"Citrome","year":"2020","journal-title":"The Journal of clinical psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0008","unstructured":"Corporation, M. (2019) Microsoft Access. https:\/\/office.microsoft.com\/access."},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0009","doi-asserted-by":"crossref","first-page":"155","DOI":"10.31887\/DCNS.2011.13.2\/ccorrell","article-title":"Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives","volume":"13","author":"Correll","year":"2011","journal-title":"Dialog. Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41537-020-00127-y","article-title":"Efficacy and safety of once-monthly Risperidone ISM(\u00ae) in schizophrenic patients with an acute exacerbation","volume":"6","author":"Correll","year":"2020","journal-title":"NPJ Schizophr."},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0011","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1177\/0962280218773122","article-title":"One-stage dose\u2013response meta-analysis for aggregated data","volume":"28","author":"Crippa","year":"2019","journal-title":"Stat. Methods Med. Res."},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0012","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12874-016-0189-0","article-title":"Dose-response meta-analysis of differences in means","volume":"16","author":"Crippa","year":"2016","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0013","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0014","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/JCP.0b013e3182977308","article-title":"High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study","volume":"33","author":"Goff","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0015","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0016","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","author":"Higgins","year":"2011"},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0017","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4088\/JCP.10m06194","article-title":"A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder","volume":"73","author":"Honer","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0018","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0019","series-title":"Evaluation and Diagnosis of Drug-induced Extrapyramidal Symptoms: Commentary on the DIEPSS and Guide to Its Usage","author":"Inada","year":"1996"},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0020","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1176\/appi.ajp.160.6.1125","article-title":"Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic","volume":"160","author":"Kane","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0021","doi-asserted-by":"crossref","first-page":"627","DOI":"10.4088\/JCP.08r04210","article-title":"Akathisia: an updated review focusing on second-generation antipsychotics","volume":"70","author":"Kane","year":"2009","journal-title":"J. Clinic. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0022","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.4088\/JCP.14m09168","article-title":"Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study","volume":"75","author":"Kane","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0023","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1586\/14737175.5.3.297","article-title":"Aripiprazole: pharmacology, efficacy, safety and tolerability","volume":"5","author":"Kinghorn","year":"2005","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0024","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00406-018-0869-3","article-title":"Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis","volume":"268","author":"Krause","year":"2018","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0025","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/JCP.0b013e3182983ffa","article-title":"Estimating dopamine D\u2082 receptor occupancy for doses of 8 antipsychotics: a meta-analysis","volume":"33","author":"Lako","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0026","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/026988119801200212","article-title":"SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment","volume":"12","author":"Lane","year":"1998","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0027","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1600-0447.2006.00887.x","article-title":"The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial","author":"Lecrubier","year":"2006","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0028","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1176\/appi.ajp.2019.19010034","article-title":"Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia","volume":"177","author":"Leucht","year":"2020","journal-title":"Amer. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0029","unstructured":"Leucht, S., Hamza, T., Siafis, S., Wu, H., Schneider-Thoma, J. & Davis, J. (2020b) Dose-response meta-analysis of the efficacy and side-effects of antipsychotic drugs in schizophrenia. PROSPERO, CRD42020181467."},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0030","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/JCP.0b013e31820f4fe0","article-title":"A randomized, double-blind, parallel-group, fixed-dose, clinical trial of quetiapine at 600 versus 1200mg\/d for patients with treatment-resistant schizophrenia or schizoaffective disorder","volume":"31","author":"Lindenmayer","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0031","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1192\/pb.bp.114.048793","article-title":"Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression","volume":"39","author":"Loebel","year":"2015","journal-title":"BJPsych Bull."},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0032","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.4088\/JCP.14m09741","article-title":"A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia","volume":"76","author":"Meltzer","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0033","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/JCP.0000000000001205","article-title":"lurasidone improves psychopathology and cognition in treatment-resistant Schizophrenia","volume":"40","author":"Meltzer","year":"2020","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0034","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/JCP.0000000000000479","article-title":"Efficacy, safety, and tolerability of RBP-7000 once-monthly risperidone for the treatment of acute schizophrenia: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study","volume":"36","author":"Nasser","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0036","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s40265-020-01312-0","article-title":"Treatment of antipsychotic-induced akathisia: role of serotonin 5-HT2a receptor antagonists","volume":"80","author":"Poyurovsky","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0037","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/0706743718760288","article-title":"The assessment and treatment of antipsychotic-induced akathisia","volume":"63","author":"Pringsheim","year":"2018","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0038","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1600-0447.1998.tb10044.x","article-title":"Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol","volume":"98","author":"Puech","year":"1998","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0039","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/archpsyc.1983.01790220026004","article-title":"Akathisia with haloperidol and thiothixene","volume":"41","author":"Putten","year":"1984","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0040","doi-asserted-by":"crossref","DOI":"10.7326\/M22-1507","article-title":"The impact of the COVID-19 pandemic and associated control measures on the mental health of the general population : a systematic review and dose-response meta-analysis","author":"Salanti","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0041","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2174\/1570159X14666161208153644","article-title":"Revisiting antipsychotic-induced akathisia: current issues and prospective challenges","volume":"15","author":"Salem","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0042","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jamapsychiatry.2015.2955","article-title":"Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis","volume":"73","author":"Samara","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0043","article-title":"Increasing antipsychotic dose for non response in schizophrenia","author":"Samara","year":"2018","journal-title":"Cochrane Database System. Rev."},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0044","doi-asserted-by":"crossref","first-page":"209","DOI":"10.15171\/bi.2017.25","article-title":"Study-based registers of randomized controlled trials: starting a systematic review with data extraction or meta-analysis","volume":"7","author":"Shokraneh","year":"2017","journal-title":"Bioimpacts"},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0045","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13643-019-1035-3","article-title":"Study-based registers reduce waste in systematic reviewing: discussion and case report","volume":"8","author":"Shokraneh","year":"2019","journal-title":"Syst. Rev."},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0046","doi-asserted-by":"crossref","unstructured":"Siafis, S., Wu, H., Wang, D., Burschinski, A., Nomura, N., Takeuchi, H., Schneider-Thoma, J., Davis, J.M., Leucht, S. (2023) Antipsychotic dose, dopamine 2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose response meta-analysis. [Manuscript submitted for publication].","DOI":"10.1038\/s41380-023-02203-y"},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0047","article-title":"The mechanism of drug-induced akathsia","author":"Stahl","year":"2011","journal-title":"CNS Spectr"},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0048","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jamapsychiatry.2021.3990","article-title":"Representation and outcomes of individuals with schizophrenia seen in everyday practice who are ineligible for randomized clinical trials","volume":"79","author":"Taipale","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0049","series-title":"The Maudsley Prescribing Guidelines in Psychiatry","author":"Taylor","year":"2021"},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0050","series-title":"R: A Language and Environment for Statistical Computing. Version 4.0. 3. Vienna, Austria","author":"Team","year":"2020"},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0051","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1097\/00005650-198412000-00005","article-title":"Choosing the correct unit of analysis in Medical Care experiments","volume":"22","author":"Whiting-O'Keefe","year":"1984","journal-title":"Med. Care"},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0052","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/schbul\/sbac001","article-title":"Antipsychotic-induced weight gain: dose-response meta-analysis of randomized controlled trials","volume":"48","author":"Wu","year":"2022","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0053","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.euroneuro.2017.06.011","article-title":"How well do patients with a first episode of schizophrenia respond to antipsychotics: a systematic review and meta-analysis","volume":"27","author":"Zhu","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.03.015_bib0054","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1176\/ajp.154.6.782","article-title":"Controlled, dose response study of sertindole and haloperidol in the treatment of schizophrenia","volume":"154","author":"Zimbroff","year":"1997","journal-title":"Am. J. Psychiatry"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X23000664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X23000664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T18:06:16Z","timestamp":1760378776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X23000664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":54,"alternative-id":["S0924977X23000664"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2023.03.015","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antipsychotic-induced akathisia in adults with acute schizophrenia: A systematic review and dose-response meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2023.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}